Bio-AMD, Inc.

Point of Care (PoC) medical diagnostics is a $ multi-billion global market. Driven by patient need for self monitoring and healthcare cost savings, hand-held devices or readers offering rapid diagnostic test results are fast replacing often slow and expensive laboratory analysis across a range of chronic illnesses and medical conditions that require either regular monitoring or simple yes/no results. Bio-AMD has positioned itself as a leading innovator in the field of reader technology development. The first stage of our corporate strategy is to develop our two most advanced patented technology platforms to a point where they can be commercialized by third parties.